Company intelligence / Profile preview

Synbal

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Synbal is a privately held, preclinical biotechnology company using its proprietary Active Genetics gene-editing platform to develop genetically complex humanized mouse models for biopharmaceutical R&D and to generate non-viral, cell-based gene therapy candidates for rare diseases, cancer, autoimmunity, and infectious diseases, including COVID-19.[1][2][3][4][5]

Therapeutic areas: OncologyImmunologyRare DiseasesInfectious Diseases
Modalities: Gene therapyCell therapyBiologic
Industry: Biotech

Partnerships

La Jolla Institute for Immunology (development and characterization of three-gene humanized mouse model for COVID-19 research under NIH SBIR grant)[4][5][6]

Beyond the preview

Go deeper on Synbal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synbal.

Explore the full profile